Literature DB >> 6199004

Increase of cellular murine leukemia virus reverse transcriptase in interferon-treated cells.

L W Mozes, D R Joseph.   

Abstract

The addition of mouse interferon (IFN) to AKR murine leukemia virus (MuLV)-producing NIH3T3 cells inhibited the extracellular appearance of AKR MuLV when assayed for reverse transcriptase activity or infectious virus production. IFN treatment had no detectable effect on proviral DNA formation during infection nor on the level of viral RNA in virus-producing cells. However, addition of IFN did alter the level of cellular viral reverse transcriptase activity. Chromatography of extracts from virus-producing cells on poly(G)-Sepharose columns revealed two peaks of reverse transcriptase activity. Peaks I and II eluted at 0.45 M and 0.65 M NaCl, respectively, while the cellular DNA polymerase beta eluted earlier at 0.3 M NaCl. IFN treatment of these chronic virus producer cells resulted in a 5-fold increase in peak I whereas peak II and polymerase beta remained essentially unchanged. When reverse transcriptase from purified virions was similarly chromatographed on poly(G)-Sepharose, all of the enzymatic activity eluted as peak I. Thus, the reverse transcriptase in peak I from cell extracts appears to be the form which is present in mature virions. Contrary to the results with chronic virus-producing cells, IFN treatment prior to exogenous infection with MuLV did not alter levels of reverse transcriptase peaks I and II or polymerase beta. These results provide further evidence that the major effect of IFN occurs at the level of MuLV maturation and assembly.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199004     DOI: 10.1007/bf01310817

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  13 in total

1.  Infectious viral DNA of murine leukemia virus.

Authors:  D Smotkin; A M Gianni; S Rozenblatt; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205

2.  Rapid cell culture assay technic for murine leukaemia viruses.

Authors:  R H Bassin; N Tuttle; P J Fischinger
Journal:  Nature       Date:  1971-02-19       Impact factor: 49.962

3.  Intracellular production of virus particles and viral components in NIH/3T3 cells chronically infected with Moloney murine leukemia virus: effect of interferon.

Authors:  M Aboud; R Kimchi; M Bakhanashvili; S Salzberg
Journal:  J Virol       Date:  1981-12       Impact factor: 5.103

4.  High molecular weight viral reverse transcriptase in Moloney sarcoma virus transformed cells.

Authors:  M Rokutanda; Y Maeda; N Watanabe
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

5.  Synthesis and cleavage processing of oncornavirus proteins during interferon inhibition of virus particle release.

Authors:  S Z Shapiro; M Strand; A Billiau
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

6.  Effect of interferon on exogenous, endogenous, and chroniv murine leukemia virus infection.

Authors:  P M Pitha; W P Rowe; M N Oxman
Journal:  Virology       Date:  1976-04       Impact factor: 3.616

7.  Two active forms of RD-114 virus DNA polymerase in infected cells.

Authors:  B I Gerwin; S G Smith; P T Peebles
Journal:  Cell       Date:  1975-09       Impact factor: 41.582

8.  Rescue of SV40 from interferon-treated heterokaryons.

Authors:  L W Mozes
Journal:  Arch Virol       Date:  1982       Impact factor: 2.574

9.  Antiretroviral effect of interferon: proposed mechanism.

Authors:  R B Naso; Y H Wu; C A Edbauer
Journal:  J Interferon Res       Date:  1982

10.  Separation of cellular and viral DNA polymerases by affinity chromatography on polynucleotide-Sepharose.

Authors:  D R Joseph; F T Kenney; J G Farrelly
Journal:  Cancer Biochem Biophys       Date:  1976-08
View more
  1 in total

1.  PolyI.polyC12U-mediated inhibition of loss of alloantigen responsiveness viral replication in human CD4+ T cell clones exposed to human immunodeficiency virus in vitro.

Authors:  J Laurence; J Kulkosky; S M Friedman; D N Posnett; P O Ts'o
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.